Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind active-controlled study of quinolixin tablets in benign prostatic hyperplasia
CTR20241404Phase 2Completed
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of quinolixin in benign prostatic hyperplasia (BPH), sponsored by Shanghai Institute of Materia Medica. Started Apr 2024; status: completed.
02
Drugs
quinolixin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on CTR20241404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241404.